AHP VERDIA (TASOSARTAN) NDA FILED IN DECEMBER; NAPRELAN POSTS $51.7 MIL. SALES IN U.S.; LODINE SYSTEM FROM ELAN COMING; THREE HRT PATCHES IN PHASE III
American Home Products could have a new angiotensin II antagonist on the market in the U.S. for the beginning of 1998 to revitalize its U.S. cardiovascular business. The NDA for Verdia (tasosartan) was submitted to FDA in December, projecting a possible FDA action by the end of the current calendar year.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth